Can metformin cause depression and anxiety
Pro Research Analysisby 
Searched over 200M research papers
The Impact of Metformin on Depression and Anxiety: A Comprehensive Review
Introduction to Metformin and Mental Health
Metformin, a widely used antidiabetic medication, has been increasingly studied for its potential effects on mental health, particularly depression and anxiety. This article synthesizes findings from multiple research studies to explore whether metformin can cause or alleviate depression and anxiety.
Metformin's Neuroprotective Properties
Protective Role Against Neurodegeneration
Research indicates that metformin has neuroprotective properties that may counteract neurodegeneration induced by substances like methamphetamine. Studies on rats have shown that metformin can reduce depression and anxiety symptoms caused by methamphetamine by modulating oxidative stress and inflammatory parameters, and by activating specific signaling pathways such as CREB/BDNF and Akt/GSK3.
Effects on Insulin Resistance and Mental Health
Insulin resistance, a common feature of type 2 diabetes, is associated with an increased risk of depression. Metformin has been shown to promote anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids (BCAAs), which in turn enhances serotonergic neurotransmission in the brain. This suggests that metformin may alleviate depression and anxiety by improving insulin sensitivity and modulating neurotransmitter systems.
Clinical Evidence in Specific Populations
Women with Polycystic Ovary Syndrome (PCOS)
Women with PCOS often experience higher rates of depression and anxiety. A study involving women with PCOS found that those who were prescribed metformin, along with lifestyle modifications, had significantly lower odds of major depression compared to those who only received lifestyle modifications. However, no significant effect on anxiety was observed.
Elderly Populations
In older rats, metformin at higher doses significantly reduced anxiety and depression symptoms. This suggests that metformin may have beneficial effects on mental health in aging populations, potentially by improving cognitive functions and reducing oxidative stress.
Mechanistic Insights
AMPK/CREB-Mediated Histone Acetylation
Metformin has been found to ameliorate stress-induced depression-like behaviors by enhancing the expression of brain-derived neurotrophic factor (BDNF) through AMPK/CREB-mediated histone acetylation. This mechanism highlights the potential of metformin to produce antidepressant effects by promoting neuroplasticity and reducing neuroinflammation.
Impact on Methamphetamine Withdrawal
Metformin has also been shown to attenuate depressive-like behavior in mice undergoing methamphetamine withdrawal. The drug's effects were linked to improvements in oxidative stress biomarkers and neuronal damage, suggesting that metformin can help restore cellular energy homeostasis and reduce neuroinflammation.
Potential Clinical Applications
Surgical Menopause and Hormonal Deficiency
In ovariectomized rats, metformin significantly decreased depressive behavior and oxidative stress in the prefrontal cortex, indicating its potential therapeutic use in women experiencing depression due to surgical menopause or hormonal deficiencies.
Treatment-Resistant Bipolar Depression
A clinical trial involving patients with treatment-resistant bipolar depression (TRBD) found that metformin, by reversing insulin resistance, significantly improved depression and anxiety symptoms. This suggests that metformin could be a valuable adjunctive treatment for TRBD.
Major Depressive Disorder (MDD)
In patients with major depressive disorder, metformin combined with fluoxetine showed significant antidepressant effects compared to fluoxetine alone. The combination also improved various biological markers associated with depression, indicating that metformin could enhance the efficacy of conventional antidepressants.
Conclusion
The collective evidence suggests that metformin does not cause depression or anxiety; rather, it appears to have potential therapeutic benefits for these conditions. By improving insulin sensitivity, modulating neurotransmitter systems, and reducing oxidative stress and inflammation, metformin may serve as a valuable adjunctive treatment for depression and anxiety, particularly in populations with metabolic comorbidities. Further research, including randomized controlled trials, is needed to fully elucidate its mechanisms and optimize its clinical use.
Sources and full results
Most relevant research papers on this topic